Cross-sectional study examines serum neurofilament light chain's role in predicting ASCVD risk in adults, suggesting utility as a biomarker.
This cross-sectional study aimed to examine the association between serum neurofilament light chain (sNfL) and the PCE-estimated 10-year atherosclerotic cardiovascular disease (ASCVD) score using data from the 2013-2014 United States National Health and Nutrition Examination Survey for adults aged 40-75 years. The primary outcome was the estimated 10-year ASCVD risk, dichotomized at 7.5%. We performed weighted logistic regression analyses, treating natural log-transformed sNfL [log (sNfL) ] as the primary continuous exposure. Restricted cubic spline (RCS) analysis was adopted to characterize the non-linear relationship between sNfL and the estimated 10-year ASCVD risk. Furthermore, stratified analyses were conducted by age, sex, BMI, hypertension, diabetes, and dyslipidemia. This study included 1,136 participants, among whom 472 (41.5%) were classified into the higher estimated risk category (≥ 7.5%). In multivariable-adjusted models, each 1-unit increase in log (sNfL) was associated with higher odds of elevated ASCVD risk (adjusted OR = 2.34, 95%CI: 1.67-3.26). Subgroup analyses showed consistent positive associations across most strata, though the association was not significant in the 40-60-year age group. Our findings suggest a positive, non-linear association between elevated sNfL levels and a higher PCE- estimated 10-year ASCVD risk score, indicating that sNfL may serve as a candidate biomarker associated with this estimated risk. Prospective studies with incident ASCVD outcomes are required to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: